DDInter1520 DDInter1676
An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Primaquine {u} (Compound) resembles {v} (Compound) Chloroquine
Primaquine {u} may lead to a major life threatening interaction when taken with {v} Hydroxychloroquine
Primaquine {u} (Compound) binds {v} (Gene) SENP8
Primaquine {u} (Compound) downregulates {v} (Gene) PSMB8
Primaquine {u} (Compound) causes {v} (Side Effect) Nausea
Primaquine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Primaquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Primaquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romidepsin
Primaquine {u} may lead to a major life threatening interaction when taken with {v} Prilocaine
Primaquine (Compound) resembles Chloroquine (Compound)
Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Primaquine (Compound) binds SENP8 (Gene)
Primaquine (Compound) downregulates PSMB8 (Gene)
Primaquine (Compound) causes Nausea (Side Effect)
Primaquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Promazine
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Primaquine may lead to a major life threatening interaction when taken with Prilocaine